An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects

Comparison of FDA-Approved Intranasal Acute Migraine Treatment Adverse Event Profiles 

Pharmacokinetic Comparison of STS101 (DHE Nasal Powder) with Liquid Nasal Spray and Injectable DHE Formulations 

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open-label ASCEND acute migraine study

STS101 Use Reduces Migraine Frequency Over Time 

STS101 (Dihydroergotamine Nasal Powder) Shows Benefit on the Resolution of Cardinal Migraine Symptoms Photophobia, Phonophobia, and Nausea: Results From the Long-Term Phase 3 Open-Label ASCEND Study 

Dihydroergotamine (DHE) Plasma Concentration and Clinical Response Relationship: An In-Office PK/PD Study 

CYP3A4 Inhibitor Itraconazole Does Not Cause Clinically Relevant Interactions With STS101 (Dihydroergotamine Nasal Powder) 

Dihydroergotamine for migraine: Evidence for multiple modes of action: The single molecule ‘combination’ product—A narrative review

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study